166 related articles for article (PubMed ID: 24168506)
1. Review of estrogen receptor, progesterone receptor, and HER-2/neu immunohistochemistry impacts on treatment for a small subset of breast cancer patients transferring care to another institution.
Jorns JM; Healy P; Zhao L
Arch Pathol Lab Med; 2013 Nov; 137(11):1660-3. PubMed ID: 24168506
[TBL] [Abstract][Full Text] [Related]
2. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
3. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
4. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
5. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.
Liu C; Zhang H; Shuang C; Lu Y; Jin F; Xu H; Lu P
Med Oncol; 2010 Sep; 27(3):747-52. PubMed ID: 19657752
[TBL] [Abstract][Full Text] [Related]
6. Breast Cancer in Men: a Report from the Department of Radiation Oncology in Kermanshah Province, Iran.
Amirifard N; Sadeghi E
Asian Pac J Cancer Prev; 2016; 17(5):2593-6. PubMed ID: 27268636
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
Hussein IA; Ahmed ST; Hameedi AD; Naji RZ; Alharbawi L; Alkhaytt M; Pity IS
Asian Pac J Cancer Prev; 2020 Apr; 21(4):1025-1029. PubMed ID: 32334465
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast.
Rody A; Diallo R; Poremba C; Speich R; Wuelfing P; Kissler S; Solbach C; Kiesel L; Jackisch C
Oncol Rep; 2004 Oct; 12(4):695-9. PubMed ID: 15375487
[TBL] [Abstract][Full Text] [Related]
9. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
Słodkowska J; Filas V; Buszkiewicz E; Trzeciak P; Wojciechowski M; Koktysz R; Staniszewski W; Breborowicz J; Rojo MG
Folia Histochem Cytobiol; 2010 Jan; 48(1):19-25. PubMed ID: 20529811
[TBL] [Abstract][Full Text] [Related]
10. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.
Nyagol J; Nyong'o A; Byakika B; Muchiri L; Cocco M; de Santi MM; Spina D; Bellan C; Lazzi S; Kostopoulos I; Luzi P; Leoncini L
Anal Quant Cytol Histol; 2006 Apr; 28(2):97-103. PubMed ID: 16637512
[TBL] [Abstract][Full Text] [Related]
11. Comparison of estrogen receptors, progesterone receptors and HER-2/neu expression between primary and metastatic breast carcinoma.
Azam M; Qureshi A; Mansoor S
J Pak Med Assoc; 2009 Nov; 59(11):736-40. PubMed ID: 20361669
[TBL] [Abstract][Full Text] [Related]
12. In situ and invasive components of mammary adenocarcinoma: comparison of Her-2/neu status.
Layfield LJ; Lewis C
Anal Quant Cytol Histol; 2007 Aug; 29(4):239-43. PubMed ID: 17879632
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic characteristics of male breast cancer: a report of 21 cases in radiotherapy center of hamedan, iran.
Sedighi A; Hamed EA; Mohammadian K; Behnood S; Kalaghchi B
Asian Pac J Cancer Prev; 2013; 14(12):7381-3. PubMed ID: 24460307
[TBL] [Abstract][Full Text] [Related]
14. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
[TBL] [Abstract][Full Text] [Related]
15. [Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer].
Wang B; Guan ZZ; Liu DG; Lin TY; Zhang L; Xia ZJ; Teng XY
Ai Zheng; 2004 Dec; 23(12):1710-3. PubMed ID: 15601567
[TBL] [Abstract][Full Text] [Related]
16. Male breast cancer: A 10 year retrospective case series in a tertiary care hospital.
Yetkin G; Celayir MF; Tanik C; Citgez B; Uludag M; Mihmanli M
J Pak Med Assoc; 2019 Aug; 69(8):1209-1212. PubMed ID: 31431782
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications.
Ciocca DR; Gago FE; Fanelli MA; Calderwood SK
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):32-40. PubMed ID: 17049840
[TBL] [Abstract][Full Text] [Related]
18. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
De La Cruz LM; Harhay MO; Zhang P; Ugras S
Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
[TBL] [Abstract][Full Text] [Related]
19. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
Recăreanu F; Simionescu C; Georgescu CV; Pirici E
Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
[TBL] [Abstract][Full Text] [Related]
20. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
